Telbivudine (N = 139) | Control (N = 102) | P value | |
---|---|---|---|
HBV DNA, log10 IU/mL, median (range) | |||
Week 2 | 5.51 (3.04–8.06) | 7.74 (6.03–9.00) | < 0.001 |
Week 4 | 4.12 (2.70–7.43) | 7.70 (6.03–9.00) | < 0.001 |
Week 8 | 3.20 (2.70–6.76) | 7.74 (6.03–9.00) | < 0.001 |
At delivery | 2.82 (2.70–6.45) | 7.72 (5.32–9.00) | < 0.001 |
ALT levels at delivery, U/L, median (range) | 28 (11–238) | 47 (8–217) | < 0.001 |
Normalization rate of ALT, n (%) | 105 (75.5%) | 52 (51%) | < 0.001 |
AST levels at delivery, U/L, median (range) | 27 (11–141) | 39 (17–144) | < 0.001 |
Normalization rate of AST, n (%) | 112 (80.6%) | 55 (53.9%) | < 0.001 |
TBIL levels at delivery, U/L, median (range) | 1.1 (9.8–36.0) | 9.5 (3.8–48.6) | 0.459 |
Normalization rate of TBIL, n (%) | 137 (98.6%) | 100 (98.0%) | 1.000 |
HBeAg positive at delivery, n (%) | 108 (77.7%) | 91 (89.2%) | 0.025 |